RPRaphael Simon Peter

Raphael Simon Peter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raphael Simon Peter has a total of 273 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response to the Comment on our Article (Cerebral gray matter volumes in long-term post-COVID patients are associated with peripheral kynurenine pathway metabolites and the severity of depressive symptoms)

    by Lynn Matits, Jana Schellenberg, Alexander Rau, Iris-Tatjana Kolassa, Dietrich Rothenbacher, Raphael S. Peter, Winfried V. Kern, Meinrad Beer, Benjamin Bender, Marianne Schell, et al.

  • Open Access

    Development of a symptom-based severity score anchored to health-related quality of life post-COVID-19 within the population-based EPILOC cohorts

    by Raphael Simon Peter, Lisamaria Sedelmaier, Alexandra Nieters, Claudia Schilling, Lynn Matits, Siri Goepel, Uta Merle, Juergen M. Steinacker, Dietrich Rothenbacher, Winfried V. Kern

    Purpose: Because simple symptom counts treat all symptoms as equally important and may not adequately capture the HRQoL impact of heterogeneous post-COVID-19 symptoms, we aimed to develop an HRQoL-anchored symptom severity score providing an interpretable measure of post-COVID-19 disease burden. Methods: Baseline data from the population-based EPILOC and EPILOC Omicron surveys (adults aged 18–65 years) were used to develop a symptom-based severity score anchored to physical and mental HRQoL assessed with the SF-12. A two-stage modelling approach was applied to identify HRQoL-relevant symptoms and to derive symptom-specific weights for physical and mental component scores, incorporating 30 ordinal symptom severity variables. Symptom-specific weights were extracted to compute physical, mental, and composite severity scores. Score interpretation was examined using external reference measures, including EPILOC case status, self-reported health recovery, and functional consequences. Results: A total of 19,004 participants (mean age 44.3 years, 59.6% female) were included. Sixteen symptoms contributed to the physical and eleven to the mental HRQoL score, with a limited subset accounting for most of the HRQoL loss. Severity scores were heavily right-skewed, with 50.6% of participants showing no measurable HRQoL impairment. Higher scores correlated with lower self-reported recovery, and increased probability of rehabilitation use and health-related changes in working time, supporting convergent and criterion-related validity. Conclusions: This study introduces a transparent, HRQoL-anchored symptom severity score that measures graded post-COVID-19 burden beyond simple symptom counts. The score may be particularly suited for longitudinal assessment of recovery trajectories. Plain English summary: Many people report ongoing symptoms after a COVID-19 infection, but it is hard to explain how much these symptoms impact daily life and well-being. Simply counting symptoms is not effective because some are more severe or disruptive than others. This study focuses on how to measure the overall effect of post-COVID symptoms on people’s quality of life in a clear and meaningful way. The goal was to develop a score that shows how strongly different symptoms are associated with limitations in physical and mental health. Using data from over 19,000 participants, we connected symptom severity to well-established measures of physical and mental quality of life. We found that only a few symptoms had strongly impaired daily functioning, while many others had little or no measurable effect. The resulting score clearly differentiated individuals who had fully recovered from those with ongoing health issues. Overall, this study demonstrates that a quality-of-life-based symptom score offers a clearer and more useful view of post-COVID health compared to simple symptom counts. Such a score can help researchers and healthcare providers better understand recovery and ongoing health needs after COVID-19.

  • Open Access

    Population-based comparison of post-acute sequelae of COVID-19 and health-related quality of life across pandemic periods: Omicron era versus early pandemic

    by Raphael S. Peter, Alexandra Nieters, Lisamaria Sedelmaier, Hans-Georg Kräusslich, Stefan O. Brockmann, Siri Göpel, Uta Merle, Jürgen M. Steinacker, Dietrich Rothenbacher, Winfried V. Kern, et al.

    Post-COVID-19 syndrome (PCS) may vary across pandemic phases. We compared the prevalence of post-acute COVID-19 symptom clusters following SARS-CoV-2 infection in the early pandemic and during the Omicron era using a population-based approach. The EPILOC study enrolled individuals aged 18–65 years who tested PCR-positive for SARS-CoV-2 during the early pandemic, between October 2020 and April 2021, in defined geographic regions within Baden-Württemberg. EPILOC-Omicron used an identical design for individuals infected between June and July 2022. Participants completed a standardised questionnaire assessing sociodemographics, lifestyle, symptoms, and health-related quality of life (SF-12). PCS was defined as ≤ 80% recovery of general health or work capacity plus at least one new moderate-to-strong symptom, both compared to before index infection. Generalised linear models adjusted for age, sex, and education were used to estimate relative risks (RRs). We analysed data from 11,710 EPILOC (24% response) and 12,560 EPILOC-Omicron participants (17% response). Participants were similar in age and sex distribution. Vaccination before infection differed markedly (< 3 vs. > 92%). PCS prevalence was 29.6% in EPILOC and 14.5% in EPILOC-Omicron. Predictors of PCS were similar for both. Symptom clusters were consistently less frequent after infection during the Omicron era (e.g., fatigue RR = 0.54; neurocognitive impairment RR = 0.53; chest symptoms RR = 0.47; smell/taste disorder RR = 0.17). Health-related quality of life was similar in PCS cases of both cohorts (mean SF-12 Physical 40.3 vs. 41.0, mean SF-12 Mental 38.9 vs. 40.7). PCS was less common following SARS-CoV-2 infection in the Omicron era compared to the early pandemic period. However, affected individuals continue to experience substantial, comparable impairment in hrQoL across both pandemic periods.


  • Open Access

    Incidence and Survival Rates of Frontotemporal Lobar Degeneration

    by Gabriele Nagel, Raphael Simon Peter, Zeljko Uzelac, Deborah Wernecke, Ludwig Niehaus, Thomas Trottenberg, Michael Jöbges, Christian Dettmers, Katharina Althaus, Kristina Mayer-Freitag, et al.

    Frontotemporal lobar degeneration (FTLD) can present as a behavioral or language variant (bvFTLD or a primary progressive aphasia [PPA], or as a syndrome with parkinsonism, such as corticobasal syndrome [CBS] or progressive supranuclear palsy [PSP]). The incidence of FTLD varies in epidemiologic studies, reaching 3 per 100,000 person-years. Only few data exist regarding survival times. We evaluated incidence and survival rates in a population-based registry with high coverage in Southern Germany. The epidemiologic ALS-FTLD registry Swabia covers a population of 8.4 million inhabitants in south-west Germany. Raw and age-standardized incidence rates, as well as incidence rate ratios (IRR) with 95% CIs were calculated. Median survival time was estimated for different FTLD variants using the Kaplan-Meier method. Between 2015 and 2022, 515 patients with FTLD (mean age at diagnosis 68.0 ± 9.5 years, 59.8% men) were registered. The median diagnostic delay was 24.8 months. The most common variant was bvFTLD (n = 185, 35.9%; 66.5% men), followed by PPA (n = 147, 28.5%; 51.0% men), PSP (n = 133, 25.8%; 62.9% men), and CBS (n = 22, 4.3%; 50% men). The overall FTLD incidence was 0.77 (95% CI 0.71-0.84), and the age-standardized incidence was 0.76 (95% CI 0.69-0.82) per 100.000 person-years. The age-standardized incidence was higher in men than in women, with an IRR of 1.73 (95% CI 1.44-2.00). In men, incidence increased from the age 50 years, primarily due to bvFTD, whereas in women this rise was primarily due to PSP. The median survival (N = 392) from diagnosis was 53.6 months (95% CI 50.9-62.0) overall, 73.1 months (95% CI 63.6-82.8) for patients with PPA, 42.8 months (95% CI 35.1-64.3) for patients with bvFTD, and 49.5 months (95% CI 39.2-53.7) for patients with PPS/CBS. We observed a raw incidence rate of 0.77, thus considerably lower than in most previous reports. Incidence was substantially higher in men than in women. The prognosis from the time of diagnosis depended highly on the specific FTLD subtype. Our data are based on the large sample size and high capture rate of a central European population-based registry.

  • Open Access

    Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study

    by Raphael S. Peter, Lisamaria Sedelmaier, Alexandra Nieters, Stefan O. Brockmann, Siri Göpel, Uta Merle, Jürgen M. Steinacker, Hans-Georg Kräusslich, Dietrich Rothenbacher, Winfried V. Kern


  • Top Cited Papers
    Open Access

    Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study

    by Raphael S. Peter, Alexandra Nieters, Siri Göpel, Uta Merle, Jürgen M. Steinacker, Peter Deibert, Birgit Friedmann-Bette, Andreas Nieß, Barbara Müller, Claudia Schilling, et al.

    Background: Self-reported health problems following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are common and often include relatively non-specific complaints such as fatigue, exertional dyspnoea, concentration or memory disturbance and sleep problems. The long-term prognosis of such post-acute sequelae of COVID-19/post-COVID-19 syndrome (PCS) is unknown, and data finding and correlating organ dysfunction and pathology with self-reported symptoms in patients with non-recovery from PCS is scarce. We wanted to describe clinical characteristics and diagnostic findings among patients with PCS persisting for >1 year and assessed risk factors for PCS persistence versus improvement. Methods and findings: This nested population-based case-control study included subjects with PCS aged 18–65 years with (n = 982) and age- and sex-matched control subjects without PCS (n = 576) according to an earlier population-based questionnaire study (6–12 months after acute infection, phase 1) consenting to provide follow-up information and to undergo comprehensive outpatient assessment, including neurocognitive, cardiopulmonary exercise, and laboratory testing in four university health centres in southwestern Germany (phase 2, another 8.5 months [median, range 3–14 months] after phase 1). The mean age of the participants was 48 years, and 65% were female. At phase 2, 67.6% of the patients with PCS at phase 1 developed persistent PCS, whereas 78.5% of the recovered participants remained free of health problems related to PCS. Improvement among patients with earlier PCS was associated with mild acute index infection, previous full-time employment, educational status, and no specialist consultation and not attending a rehabilitation programme. The development of new symptoms related to PCS among participants initially recovered was associated with an intercurrent secondary SARS-CoV-2 infection and educational status. Patients with persistent PCS were less frequently never smokers (61.2% versus 75.7%), more often obese (30.2% versus 12.4%) with higher mean values for body mass index (BMI) and body fat, and had lower educational status (university entrance qualification 38.7% versus 61.5%) than participants with continued recovery. Fatigue/exhaustion, neurocognitive disturbance, chest symptoms/breathlessness and anxiety/depression/sleep problems remained the predominant symptom clusters. Exercise intolerance with post-exertional malaise (PEM) for >14 h and symptoms compatible with myalgic encephalomyelitis/chronic fatigue syndrome were reported by 35.6% and 11.6% of participants with persistent PCS patients, respectively. In analyses adjusted for sex-age class combinations, study centre and university entrance qualification, significant differences between participants with persistent PCS versus those with continued recovery were observed for performance in three different neurocognitive tests, scores for perceived stress, subjective cognitive disturbances, dysautonomia, depression and anxiety, sleep quality, fatigue and quality of life. In persistent PCS, handgrip strength (40.2 [95% confidence interval (CI) [39.4, 41.1]] versus 42.5 [95% CI [41.5, 43.6]] kg), maximal oxygen consumption (27.9 [95% CI [27.3, 28.4]] versus 31.0 [95% CI [30.3, 31.6]] ml/min/kg body weight) and ventilatory efficiency (minute ventilation/carbon dioxide production slope, 28.8 [95% CI [28.3, 29.2]] versus 27.1 [95% CI [26.6, 27.7]]) were significantly reduced relative to the control group of participants with continued recovery after adjustment for sex-age class combinations, study centre, education, BMI, smoking status and use of beta blocking agents. There were no differences in measures of systolic and diastolic cardiac function at rest, in the level of N-terminal brain natriuretic peptide blood levels or other laboratory measurements (including complement activity, markers of Epstein–Barr virus [EBV] reactivation, inflammatory and coagulation markers, serum levels of cortisol, adrenocorticotropic hormone and dehydroepiandrosterone sulfate). Screening for viral persistence (PCR in stool samples and SARS-CoV-2 spike antigen levels in plasma) in a subgroup of the patients with persistent PCS was negative. Sensitivity analyses (pre-existing illness/comorbidity, obesity, medical care of the index acute infection) revealed similar findings. Patients with persistent PCS and PEM reported more pain symptoms and had worse results in almost all tests. A limitation was that we had no objective information on exercise capacity and cognition before acute infection. In addition, we did not include patients unable to attend the outpatient clinic for whatever reason including severe illness, immobility or social deprivation or exclusion. Conclusions: In this study, we observed that the majority of working age patients with PCS did not recover in the second year of their illness. Patterns of reported symptoms remained essentially similar, non-specific and dominated by fatigue, exercise intolerance and cognitive complaints. Despite objective signs of cognitive deficits and reduced exercise capacity, there was no major pathology in laboratory investigations, and our findings do not support viral persistence, EBV reactivation, adrenal insufficiency or increased complement turnover as pathophysiologically relevant for persistent PCS. A history of PEM was associated with more severe symptoms and more objective signs of disease and might help stratify cases for disease severity.


  • Open Access

    Real-world mobility recovery after hip fracture: secondary analyses of digital mobility outcomes from four randomized controlled trials

    by Monika Engdal, Kristin Taraldsen, Carl-Philipp Jansen, Raphael Simon Peter, Beatrix Vereijken, Clemens Becker, Jorunn Laegdheim Helbostad, Jochen Klenk

    Background: The main focus of rehabilitation following hip fracture is to regain mobility. Objectives: To estimate the progression of real-world mobility the first year after hip fracture using digital mobility outcomes. Design: An exploratory, prospective cohort study with pooled data from four previously conducted clinical trials. Setting and Subjects: We combined data from the Trondheim Hip Fracture Trial and Eva-Hip Trial in Trondheim, Norway, and the PROFinD 1 and PROFinD 2 trials in Stuttgart and Heidelberg, Germany, resulting in a sample of 717 hip fracture patients aged ≥65 years. Methods: Each of the trials assessed mobility using body-fixed sensors (activPAL) at three time points, collectively providing observations across the entire first year post-surgery. The following 24-h DMOs were calculated: total walking duration (minutes), maximum number of steps within a walking bout, and number of sit-to-stand-to-walk transfers. Continuous 1-year progression of the median, the 25th percentile, and the 75th percentile were estimated using quantile regression models with splines. Results: The dataset contained 5909 observation days. The median daily total walking duration increased until 36 weeks post-surgery reaching 40 min; daily maximum number of steps within a walking bout increased during the first eight weeks and then stabilized at less than 100 steps; daily sit-to-stand-to-walk transfers reached a plateau after 6 weeks with less than 40 transfers. Conclusions: The three DMOs progressed differently and attained plateau levels at varying times during the first year after hip fracture, indicating that these Digital Mobility Outcomes provide complementary information about different aspects of mobility recovery.


  • Open Access

    Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: population-based, nested case-control study

    by Raphael S. Peter, Alexandra Nieters, Siri Göpel, Uta Merle, Jürgen M. Steinacker, Peter Deibert, Birgit Friedmann-Bette, Andreas Niess, Barbara Müller, Claudia Schilling, et al.

    Objective: To assess risk factors for persistence vs improvement and to describe clinical characteristics and diagnostic evaluation of subjects with post-acute sequelae of COVID-19/post-COVID-19 syndrome (PCS) persisting for more than one year. Design: Nested population-based case-control study. Setting: Comprehensive outpatient assessment, including neurocognitive, cardiopulmonary exercise, and laboratory testing in four university health centres in southwestern Germany (2022). Participants: PCS cases aged 18 to 65 years with (n=982) and age and sex-matched controls without PCS (n=576) according to an earlier population-based questionnaire study (six to 12 months after acute infection, phase 1) consenting to provide follow-up information and to undergo clinical diagnostic assessment (phase 2, another 8.5 months [median] after phase 1). Main outcome measures: Relative frequencies of symptoms and health problems and distribution of symptom scores and diagnostic test results between persistent cases and controls. Additional analysis included predictors of changing case or control status over time with adjustments for potentially confounding variables. Results: At the time of clinical examination (phase 2), 67.6% of the initial cases (phase 1) remained cases, whereas 78.5% of the controls continued to report no health problems related to PCS. In adjusted analyses, predictors of improvement among cases were mild acute index infection, previous full-time employment, educational status, and no specialist consultation and not attending a rehabilitation programme. Among controls, predictors of new symptoms or worsening with PCS development were an intercurrent secondary SARS-CoV-2 infection and educational status. At phase 2, persistent cases were less frequently never smokers, had higher values for BMI and body fat, and had lower educational status than controls. Fatigue/exhaustion, neurocognitive disturbance, chest symptoms/breathlessness and anxiety/depression/sleep problems remained the predominant symptom clusters, and exercise intolerance with post-exertional malaise for >14 h (PEM) and symptoms compatible with ME/CFS (according to Canadian consensus criteria) were reported by 35.6% and 11.6% of persistent cases, respectively. In adjusted analyses, significant differences between persistent cases and stable controls (at phase 2) were observed for neurocognitive test performances, scores for perceived stress and subjective cognitive disturbances, symptoms indicating dysautonomia, depression and anxiety, sleep quality, fatigue, and quality of life. In persistent cases, handgrip strength, maximal oxygen consumption, and ventilator efficiency were significantly reduced. However, there were no differences in measures of systolic and diastolic cardiac function, in the level of pro-BNP blood levels or other laboratory measurements (including complement activity, serological markers of EBV reactivation, inflammatory and coagulation markers, cortisol, ACTH and DHEA-S serum levels). Screening for viral persistence (based on PCR in stool samples and SARS-CoV-2 spike antigen levels in plasma in a subgroup of the cases) was negative. Sensitivity analyses (pre-existing illness/comorbidity, obesity, PEM, medical care of the index acute infection) revealed similar findings and showed that persistent cases with PEM reported more pain symptoms and had worse results in almost all tests. Conclusions: This nested population-based case-control study demonstrates that the majority of PCS cases do not recover in the second year of their illness, with patterns of reported symptoms remaining essentially similar, nonspecific and dominated by fatigue, exercise intolerance and cognitive complaints. We found objective signs of cognitive deficits and reduced exercise capacity likely to be unrelated to primary cardiac or pulmonary dysfunction in some of the cases, but there was no major pathology in laboratory investigations. A history of PEM >14 h which was associated with more severe symptoms as well as with more objective signs of disease may be a pragmatic means to stratify cases for disease severity. What is already known on this topic: Self-reported health problems following SARS-CoV-2 infection have commonly been described and may persist for months. They typically include relatively non-specific complaints such as fatigue, exertional dyspnoea, concentration or memory disturbance and sleep problems. The incidence of this post-COVID-19 syndrome (PCS) is varying and associated with sociodemographic variables, pre-existing disease and comorbidities, the severity of the acute SARS-CoV-2 index infection, and some other factors. The long-term prognosis is unknown and may differ for different symptoms or symptom clusters. Evidence of measurable single or multiple organ dysfunction and pathology and their correlation with self-reported symptoms in patients with non-recovery from PCS for more than a year have not been well described. What this study adds: The study describes the severity of the index infection, lower educational status, no previous full-time employment, and (need for) specialist consultation or a rehabilitation programme (the latter probably due to reverse causation) as factors for non-recovery from PCS, and found no major changes in symptom clusters among PCS cases persisting for more than a year. After a comprehensive medical evaluation of cases and controls and adjusted analyses, objective signs of organ dysfunction and pathology among persistent PCS cases correlated with self-reported symptoms, were detected more often among cases with longer lasting post-exertional malaise, and included both reduced physical exercise capacity (diminished handgrip strength, maximal oxygen consumption and ventilatory efficiency), and reduced cognitive test performances while there were no differences in the results of multiple laboratory investigations after adjustment for possible confounders.


  • Open Access

    Post-COVID syndrome and work ability 9-12 months after a SARS-CoV-2 infection among over 9000 employees from the general population

    by Stefanie Braig, Raphael S. Peter, Alexandra Nieters, Hans-Georg Kräusslich, Stefan O. Brockmann, Siri Göpel, Gerhard Kindle, Uta Merle, Jürgen M. Steinacker, Winfried V. Kern, et al.


  • Open Access

    Association of BMI with general health, working capacity recovered, and post‐acute sequelae of COVID‐19

    by Raphael S. Peter, Alexandra Nieters, Stefan O. Brockmann, Siri Göpel, Gerhard Kindle, Uta Merle, Jürgen M. Steinacker, Winfried V. Kern, Dietrich Rothenbacher, for the EPILOC Phase 1 Study Group

    Objective: The aim of this study was to determine the risk of post‐acute sequelae of COVID‐19 associated with the continuous spectrum of BMI.Methods: Epidemiology of Long COVID (EPILOC) is a population‐based study conducted in Baden‐Württemberg (Germany), including subjects aged 18 to 65 years who tested positive for SARS‐CoV‐2 between October 2020 and April 2021. Eligible subjects answered a standardized questionnaire, including sociodemographic characteristics, lifestyle factors, and the presence of specific symptoms. Participants assessed their current general health recovery and working capacity compared with the pre‐infection situation and provided their body height and weight. Generalized additive models were used to assess the association of BMI with general health recovered, working capacity recovered, and prevalence of fatigue, cognitive impairment, and chest symptoms.Results: The analyses included 11,296 individuals (41% male), with a mean age of 44.0 (SD 13.7) years. Best general health recovery was observed at BMI of 22.1 (95% CI: 21.0‐27.0) kg/m2 in men and BMI of 21.6 (95% CI: 20.3‐23.1) kg/m2 in women. In addition, we found that increasing BMI was consistently associated with post‐COVID fatigue, neurocognitive impairment, and chest symptoms.Conclusions: High BMI contributes to impaired recovery after SARS‐CoV‐2 infection; however, a low BMI is associated with impaired recovery as well.